ID   KPYM_HUMAN              Reviewed;         531 AA.
AC   P14618; A6NFK3; B2R5N8; B3KRY0; B4DFX8; B4DUU6; P14786; Q53GK4;
AC   Q96E76; Q9BWB5; Q9UCV6; Q9UPF2;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   10-MAY-2017, entry version 225.
DE   RecName: Full=Pyruvate kinase PKM;
DE            EC=2.7.1.40;
DE   AltName: Full=Cytosolic thyroid hormone-binding protein;
DE            Short=CTHBP;
DE   AltName: Full=Opa-interacting protein 3;
DE            Short=OIP-3;
DE   AltName: Full=Pyruvate kinase 2/3;
DE   AltName: Full=Pyruvate kinase muscle isozyme;
DE   AltName: Full=Thyroid hormone-binding protein 1;
DE            Short=THBP1;
DE   AltName: Full=Tumor M2-PK;
DE   AltName: Full=p58;
GN   Name=PKM; Synonyms=OIP3, PK2, PK3, PKM2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM M2).
RC   TISSUE=Liver;
RX   PubMed=2854097; DOI=10.1016/0378-1119(88)90515-X;
RA   Tani K., Yoshida M.C., Satoh H., Mitamura K., Noguchi T., Tanaka T.,
RA   Fujii H., Miwa S.;
RT   "Human M2-type pyruvate kinase: cDNA cloning, chromosomal assignment
RT   and expression in hepatoma.";
RL   Gene 73:509-516(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM M2), PROTEIN SEQUENCE OF 70-98,
RP   SUBUNIT, AND ENZYME REGULATION.
RX   PubMed=2813362; DOI=10.1073/pnas.86.20.7861;
RA   Kato H., Fukuda T., Parkison C., McPhie P., Cheng S.-Y.;
RT   "Cytosolic thyroid hormone-binding protein is a monomer of pyruvate
RT   kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:7861-7865(1989).
RN   [3]
RP   ERRATUM.
RA   Kato H., Fukuda T., Parkison C., McPhie P., Cheng S.-Y.;
RL   Proc. Natl. Acad. Sci. U.S.A. 87:1625-1625(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING.
RX   PubMed=2040271; DOI=10.1111/j.1432-1033.1991.tb15991.x;
RA   Takenaka M., Noguchi T., Sadahiro S., Hirai H., Yamada K., Matsuda T.,
RA   Imai E., Tanaka T.;
RT   "Isolation and characterization of the human pyruvate kinase M gene.";
RL   Eur. J. Biochem. 198:101-106(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS M1 AND 3).
RC   TISSUE=Astrocyte, and Fetal brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM M2).
RC   TISSUE=Kidney;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM M2), AND VARIANT
RP   VAL-204.
RC   TISSUE=Kidney, Lung carcinoma, Ovary, Retina, and Rhabdomyosarcoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PROTEIN SEQUENCE OF 2-43; 57-73; 93-115; 126-135; 167-186; 231-246;
RP   271-311; 401-422; 448-455 AND 490-498, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT SER-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=B-cell lymphoma;
RA   Bienvenut W.V.;
RL   Submitted (JUL-2005) to UniProtKB.
RN   [12]
RP   PROTEIN SEQUENCE OF 2-18, CATALYTIC ACTIVITY, ENZYME REGULATION,
RP   BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND INTERACTION WITH THYROID
RP   HORMONE.
RX   PubMed=1854723; DOI=10.1021/bi00243a010;
RA   Ashizawa K., McPhie P., Lin K.-H., Cheng S.-Y.;
RT   "An in vitro novel mechanism of regulating the activity of pyruvate
RT   kinase M2 by thyroid hormone and fructose 1, 6-bisphosphate.";
RL   Biochemistry 30:7105-7111(1991).
RN   [13]
RP   PROTEIN SEQUENCE OF 2-32.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [14]
RP   PROTEIN SEQUENCE OF 74-89, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, and Cajal-Retzius cell;
RA   Lubec G., Vishwanath V.;
RL   Submitted (MAR-2007) to UniProtKB.
RN   [15]
RP   PROTEIN SEQUENCE OF 174-186; 295-305 AND 401-422 (ISOFORMS M2/3),
RP   INTERACTION WITH TRIM35 (ISOFORM M2), SUBCELLULAR LOCATION, AND MASS
RP   SPECTROMETRY.
RX   PubMed=25263439; DOI=10.1038/onc.2014.325;
RA   Chen Z., Wang Z., Guo W., Zhang Z., Zhao F., Zhao Y., Jia D., Ding J.,
RA   Wang H., Yao M., He X.;
RT   "TRIM35 Interacts with pyruvate kinase isoform M2 to suppress the
RT   Warburg effect and tumorigenicity in hepatocellular carcinoma.";
RL   Oncogene 34:3946-3956(2015).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 368-531 (ISOFORM M2).
RX   PubMed=9466265; DOI=10.1046/j.1365-2958.1998.00670.x;
RA   Williams J.M., Chen G.-C., Zhu L., Rest R.F.;
RT   "Using the yeast two-hybrid system to identify human epithelial cell
RT   proteins that bind gonococcal Opa proteins: intracellular gonococci
RT   bind pyruvate kinase via their Opa proteins and require host pyruvate
RT   for growth.";
RL   Mol. Microbiol. 27:171-186(1998).
RN   [17]
RP   INTERACTION WITH HERC1.
RX   PubMed=12650930; DOI=10.1016/S0014-5793(03)00205-9;
RA   Garcia-Gonzalo F.R., Cruz C., Munoz P., Mazurek S., Eigenbrodt E.,
RA   Ventura F., Bartrons R., Rosa J.L.;
RT   "Interaction between HERC1 and M2-type pyruvate kinase.";
RL   FEBS Lett. 539:78-84(2003).
RN   [18]
RP   ISGYLATION.
RX   PubMed=16139798; DOI=10.1016/j.bbrc.2005.08.132;
RA   Giannakopoulos N.V., Luo J.K., Papov V., Zou W., Lenschow D.J.,
RA   Jacobs B.S., Borden E.C., Li J., Virgin H.W., Zhang D.E.;
RT   "Proteomic identification of proteins conjugated to ISG15 in mouse and
RT   human cells.";
RL   Biochem. Biophys. Res. Commun. 336:496-506(2005).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-105, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [22]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17308100; DOI=10.1158/0008-5472.CAN-06-2870;
RA   Stetak A., Veress R., Ovadi J., Csermely P., Keri G., Ullrich A.;
RT   "Nuclear translocation of the tumor marker pyruvate kinase M2 induces
RT   programmed cell death.";
RL   Cancer Res. 67:1602-1608(2007).
RN   [23]
RP   INTERACTION WITH PML, ENZYME REGULATION, SUBUNIT, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=18298799; DOI=10.1111/j.1365-2443.2008.01165.x;
RA   Shimada N., Shinagawa T., Ishii S.;
RT   "Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML
RT   tumor suppressor protein.";
RL   Genes Cells 13:245-254(2008).
RN   [24]
RP   INTERACTION WITH POU5F1, IDENTIFICATION BY MASS SPECTROMETRY,
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=18191611; DOI=10.1016/j.biocel.2007.11.009;
RA   Lee J., Kim H.K., Han Y.-M., Kim J.;
RT   "Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with
RT   Oct-4 in regulating transcription.";
RL   Int. J. Biochem. Cell Biol. 40:1043-1054(2008).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [28]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; TYR-175 AND THR-195,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [30]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-62; LYS-89; LYS-166; LYS-266
RP   AND LYS-433, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [33]
RP   INTERACTION WITH EGLN3 AND HIF1A, SUBCELLULAR LOCATION, INDUCTION,
RP   FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, HYDROXYLATION AT
RP   PRO-403 AND PRO-408, AND MUTAGENESIS OF PRO-403 AND PRO-408.
RX   PubMed=21620138; DOI=10.1016/j.cell.2011.03.054;
RA   Luo W., Hu H., Chang R., Zhong J., Knabel M., O'Meally R., Cole R.N.,
RA   Pandey A., Semenza G.L.;
RT   "Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-
RT   inducible factor 1.";
RL   Cell 145:732-744(2011).
RN   [34]
RP   INTERACTION WITH EGLN3.
RX   PubMed=21483450; DOI=10.1038/cr.2011.66;
RA   Chen N., Rinner O., Czernik D., Nytko K.J., Zheng D., Stiehl D.P.,
RA   Zamboni N., Gstaiger M., Frei C.;
RT   "The oxygen sensor PHD3 limits glycolysis under hypoxia via direct
RT   binding to pyruvate kinase.";
RL   Cell Res. 21:983-986(2011).
RN   [35]
RP   ACETYLATION AT LYS-305.
RX   PubMed=21700219; DOI=10.1016/j.molcel.2011.04.025;
RA   Lv L., Li D., Zhao D., Lin R., Chu Y., Zhang H., Zha Z., Liu Y.,
RA   Li Z., Xu Y., Wang G., Huang Y., Xiong Y., Guan K.L., Lei Q.Y.;
RT   "Acetylation targets the M2 isoform of pyruvate kinase for degradation
RT   through chaperone-mediated autophagy and promotes tumor growth.";
RL   Mol. Cell 42:719-730(2011).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; THR-41; TYR-105 AND
RP   SER-127, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [39]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT LYS-3, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [40]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-166, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [41]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.82 ANGSTROMS) OF ISOFORM M2 IN COMPLEX WITH
RP   OXALATE AND FBP, CATALYTIC ACTIVITY, SUBUNIT, ENZYME MECHANISM, ENZYME
RP   REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=15996096; DOI=10.1021/bi0474923;
RA   Dombrauckas J.D., Santarsiero B.D., Mesecar A.D.;
RT   "Structural basis for tumor pyruvate kinase M2 allosteric regulation
RT   and catalysis.";
RL   Biochemistry 44:9417-9429(2005).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS).
RG   Structural genomics consortium (SGC);
RT   "Structure of human muscle pyruvate kinase (PKM2).";
RL   Submitted (MAY-2005) to the PDB data bank.
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.03 ANGSTROMS) OF 14-531 ALONE AND IN COMPLEX
RP   WITH FBP, AND ENZYME REGULATION.
RX   PubMed=18337815; DOI=10.1038/nature06667;
RA   Christofk H.R., Vander Heiden M.G., Wu N., Asara J.M., Cantley L.C.;
RT   "Pyruvate kinase M2 is a phosphotyrosine-binding protein.";
RL   Nature 452:181-186(2008).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 2-531, ENZYME REGULATION BY
RP   SERINE, MAGNESIUM-BINDING SITES, SUBUNIT, AND MUTAGENESIS OF SER-437
RP   AND HIS-464.
RX   PubMed=23064226; DOI=10.1038/nature11540;
RA   Chaneton B., Hillmann P., Zheng L., Martin A.C., Maddocks O.D.,
RA   Chokkathukalam A., Coyle J.E., Jankevics A., Holding F.P.,
RA   Vousden K.H., Frezza C., O'Reilly M., Gottlieb E.;
RT   "Serine is a natural ligand and allosteric activator of pyruvate
RT   kinase M2.";
RL   Nature 491:458-462(2012).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) IN COMPLEX WITH ATP;
RP   FRUCTOSE-1-6-DIPHOSPHATE; MAGNESIUM IONS AND POTASSIUM IONS.
RX   PubMed=23530218; DOI=10.1073/pnas.1217157110;
RA   Morgan H.P., O'Reilly F.J., Wear M.A., O'Neill J.R.,
RA   Fothergill-Gilmore L.A., Hupp T., Walkinshaw M.D.;
RT   "M2 pyruvate kinase provides a mechanism for nutrient sensing and
RT   regulation of cell proliferation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:5881-5886(2013).
CC   -!- FUNCTION: Glycolytic enzyme that catalyzes the transfer of a
CC       phosphoryl group from phosphoenolpyruvate (PEP) to ADP, generating
CC       ATP. Stimulates POU5F1-mediated transcriptional activation. Plays
CC       a general role in caspase independent cell death of tumor cells.
CC       The ratio between the highly active tetrameric form and nearly
CC       inactive dimeric form determines whether glucose carbons are
CC       channeled to biosynthetic processes or used for glycolytic ATP
CC       production. The transition between the 2 forms contributes to the
CC       control of glycolysis and is important for tumor cell
CC       proliferation and survival. {ECO:0000269|PubMed:17308100,
CC       ECO:0000269|PubMed:18191611, ECO:0000269|PubMed:21620138}.
CC   -!- CATALYTIC ACTIVITY: ATP + pyruvate = ADP + phosphoenolpyruvate.
CC       {ECO:0000269|PubMed:15996096, ECO:0000269|PubMed:1854723}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000305|PubMed:23530218};
CC   -!- COFACTOR:
CC       Name=K(+); Xref=ChEBI:CHEBI:29103;
CC         Evidence={ECO:0000305|PubMed:23530218};
CC   -!- ENZYME REGULATION: Isoform M2 is allosterically activated by D-
CC       fructose 1,6-bisphosphate (FBP). Inhibited by oxalate and 3,3',5-
CC       triiodo-L-thyronine (T3). The activity of the tetrameric form is
CC       inhibited by PML. Selective binding to tyrosine-phosphorylated
CC       peptides releases the allosteric activator FBP, leading to
CC       inhibition of PKM enzymatic activity, this diverts glucose
CC       metabolites from energy production to anabolic processes when
CC       cells are stimulated by certain growth factors. Glycolytic flux
CC       are highly dependent on de novo biosynthesis of serine and
CC       glycine, and serine is a natural ligand and allosteric activator
CC       of isoform M2. {ECO:0000269|PubMed:15996096,
CC       ECO:0000269|PubMed:18298799, ECO:0000269|PubMed:18337815,
CC       ECO:0000269|PubMed:1854723, ECO:0000269|PubMed:23064226,
CC       ECO:0000269|PubMed:2813362}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=2.7 mM for phosphoenolpyruvate (at 32 degrees Celsius, pH
CC         8.0) {ECO:0000269|PubMed:15996096, ECO:0000269|PubMed:1854723};
CC         KM=0.17 mM for phosphoenolpyruvate (in the presence of 2 mM D-
CC         fructose 1,6-bisphosphate (FBP), at 32 degrees Celsius, pH 8.0)
CC         {ECO:0000269|PubMed:15996096, ECO:0000269|PubMed:1854723};
CC         KM=0.34 mM for ADP (at 32 degrees Celsius, pH 8.0)
CC         {ECO:0000269|PubMed:15996096, ECO:0000269|PubMed:1854723};
CC         KM=0.24 mM for ADP (in the presence of 2 mM FBP, at 32 degrees
CC         Celsius, pH 8.0) {ECO:0000269|PubMed:15996096,
CC         ECO:0000269|PubMed:1854723};
CC         KM=0.13 mM for phosphoenolpyruvate (in the presence of 2 mM FBP,
CC         at 25 degrees Celsius) {ECO:0000269|PubMed:15996096,
CC         ECO:0000269|PubMed:1854723};
CC         KM=0.63 mM for ADP (in the presence of 2 mM FBP, at 25 degrees
CC         Celsius) {ECO:0000269|PubMed:15996096,
CC         ECO:0000269|PubMed:1854723};
CC       pH dependence:
CC         Optimum pH for T3 binding is 6.0-6.5. Increase in pH causes T3
CC         binding to drop, does not bind T3 above pH 9.0 or below pH 5.0.
CC         {ECO:0000269|PubMed:15996096, ECO:0000269|PubMed:1854723};
CC   -!- PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-
CC       glyceraldehyde 3-phosphate: step 5/5.
CC   -!- SUBUNIT: Monomer and homotetramer. Exists as a monomer in the
CC       absence of D-fructose 1,6-bisphosphate (FBP), and reversibly
CC       associates to form a homotetramer in the presence of FBP. The
CC       monomeric form binds T3. Tetramer formation induces pyruvate
CC       kinase activity. The tetrameric form has high affinity for the
CC       substrate and is associated within the glycolytic enzyme complex.
CC       Exists in a nearly inactive dimeric form in tumor cells and the
CC       dimeric form has less affinity for the substrate. Binding to
CC       certain oncoproteins such as HPV-16 E7 oncoprotein can trigger
CC       dimerization. FBP stimulates the formation of tetramers from
CC       dimers. Interacts with HERC1, POU5F1 and PML. Interacts (isoform
CC       M2) with EGLN3; the interaction hydroxylates PKM under hypoxia and
CC       enhances binding to HIF1A. Interacts (isoform M2) with HIF1A; the
CC       interaction is enhanced by binding of EGLN3, promoting enhanced
CC       transcription activity under hypoxia. Interacts (isoform M2, but
CC       not isoform M1) with TRIM35; this interaction prevents FGFR1-
CC       dependent tyrosine phosphorylation (PubMed:25263439).
CC       {ECO:0000269|PubMed:12650930, ECO:0000269|PubMed:15996096,
CC       ECO:0000269|PubMed:18191611, ECO:0000269|PubMed:18298799,
CC       ECO:0000269|PubMed:18337815, ECO:0000269|PubMed:1854723,
CC       ECO:0000269|PubMed:21483450, ECO:0000269|PubMed:21620138,
CC       ECO:0000269|PubMed:23064226, ECO:0000269|PubMed:25263439,
CC       ECO:0000269|PubMed:2813362}.
CC   -!- INTERACTION:
CC       Q9WMX2:- (xeno); NbExp=4; IntAct=EBI-353408, EBI-710918;
CC       P10398:ARAF; NbExp=2; IntAct=EBI-353408, EBI-365961;
CC       P49407:ARRB1; NbExp=3; IntAct=EBI-353408, EBI-743313;
CC       P32121:ARRB2; NbExp=4; IntAct=EBI-353408, EBI-714559;
CC       P53355:DAPK1; NbExp=3; IntAct=EBI-353408, EBI-358616;
CC       Q9H6Z9:EGLN3; NbExp=2; IntAct=EBI-4304679, EBI-1175354;
CC       Q16665:HIF1A; NbExp=7; IntAct=EBI-4304679, EBI-447269;
CC       P68431:HIST1H3D; NbExp=3; IntAct=EBI-4304679, EBI-79722;
CC       P42858:HTT; NbExp=3; IntAct=EBI-353408, EBI-466029;
CC       P27361:MAPK3; NbExp=3; IntAct=EBI-4304679, EBI-73995;
CC       P04049:RAF1; NbExp=3; IntAct=EBI-353408, EBI-365996;
CC       Q9BSI4:TINF2; NbExp=2; IntAct=EBI-353408, EBI-717399;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:25263439}.
CC       Nucleus. Note=Translocates to the nucleus in response to different
CC       apoptotic stimuli. Nuclear translocation is sufficient to induce
CC       cell death that is caspase independent, isoform-specific and
CC       independent of its enzymatic activity.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=M2; Synonyms=M2-PK, PKM2;
CC         IsoId=P14618-1; Sequence=Displayed;
CC       Name=M1; Synonyms=M1-PK, PKM1;
CC         IsoId=P14618-2, P14786-1;
CC         Sequence=VSP_011101;
CC       Name=3;
CC         IsoId=P14618-3; Sequence=VSP_043370;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Specifically expressed in proliferating cells,
CC       such as embryonic stem cells, embryonic carcinoma cells, as well
CC       as cancer cells. {ECO:0000269|PubMed:18191611}.
CC   -!- PTM: ISGylated. {ECO:0000269|PubMed:16139798}.
CC   -!- PTM: Under hypoxia, hydroxylated by EGLN3.
CC       {ECO:0000269|PubMed:21620138}.
CC   -!- PTM: Acetylation at Lys-305 is stimulated by high glucose
CC       concentration, it decreases enzyme activity and promotes its
CC       lysosomal-dependent degradation via chaperone-mediated autophagy.
CC       {ECO:0000269|PubMed:21700219, ECO:0000269|Ref.11}.
CC   -!- PTM: FGFR1-dependent tyrosine phosphorylation is reduced by
CC       interaction with TRIM35. {ECO:0000269|PubMed:25263439}.
CC   -!- MISCELLANEOUS: There are 4 isozymes of pyruvate kinase in mammals
CC       (L, R, M1, M2) encoded by 2 different genes: PKLR and PKM. The L
CC       and R isozymes are generated from the PKLR by differential
CC       splicing of RNA; the M1 and M2 forms are produced from the PKM
CC       gene by differential splicing. L type is major isozyme in the
CC       liver, R is found in red cells, M1 is the main form in muscle,
CC       heart and brain, and M2 is found in early fetal tissues as well as
CC       in most cancer cells.
CC   -!- SIMILARITY: Belongs to the pyruvate kinase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG57589.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/pkm2/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Pyruvate kinase entry;
CC       URL="https://en.wikipedia.org/wiki/Pyruvate_kinase";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PKM2ID41728ch15q22.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M23725; AAA36449.1; -; mRNA.
DR   EMBL; M26252; AAA36672.1; -; mRNA.
DR   EMBL; X56494; CAA39849.1; -; Genomic_DNA.
DR   EMBL; AK092369; BAG52542.1; -; mRNA.
DR   EMBL; AK222927; BAD96647.1; -; mRNA.
DR   EMBL; AK294315; BAG57589.1; ALT_INIT; mRNA.
DR   EMBL; AK300800; BAG62458.1; -; mRNA.
DR   EMBL; AK312253; BAG35185.1; -; mRNA.
DR   EMBL; AY352517; AAQ15274.1; -; Genomic_DNA.
DR   EMBL; AC020779; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471082; EAW77884.1; -; Genomic_DNA.
DR   EMBL; CH471082; EAW77888.1; -; Genomic_DNA.
DR   EMBL; BC000481; AAH00481.3; -; mRNA.
DR   EMBL; BC007640; AAH07640.1; -; mRNA.
DR   EMBL; BC007952; AAH07952.3; -; mRNA.
DR   EMBL; BC012811; AAH12811.3; -; mRNA.
DR   EMBL; BC035198; AAH35198.1; -; mRNA.
DR   EMBL; AF025439; AAC39559.1; -; mRNA.
DR   CCDS; CCDS32284.1; -. [P14618-1]
DR   CCDS; CCDS32285.1; -. [P14618-2]
DR   CCDS; CCDS55972.1; -. [P14618-3]
DR   PIR; S30038; S30038.
DR   PIR; S64635; S64635.
DR   RefSeq; NP_001193725.1; NM_001206796.2.
DR   RefSeq; NP_001193726.1; NM_001206797.2.
DR   RefSeq; NP_001193727.1; NM_001206798.2. [P14618-3]
DR   RefSeq; NP_001193728.1; NM_001206799.1.
DR   RefSeq; NP_001303247.1; NM_001316318.1.
DR   RefSeq; NP_002645.3; NM_002654.5. [P14618-1]
DR   RefSeq; NP_872270.1; NM_182470.3. [P14618-2]
DR   RefSeq; NP_872271.1; NM_182471.3. [P14618-2]
DR   RefSeq; XP_005254502.1; XM_005254445.4. [P14618-1]
DR   RefSeq; XP_016877802.1; XM_017022313.1. [P14618-2]
DR   UniGene; Hs.534770; -.
DR   UniGene; Hs.704299; -.
DR   PDB; 1T5A; X-ray; 2.80 A; A/B/C/D=1-531.
DR   PDB; 1ZJH; X-ray; 2.20 A; A=3-531.
DR   PDB; 3BJF; X-ray; 2.03 A; A/B/C/D=14-531.
DR   PDB; 3BJT; X-ray; 2.50 A; A/B/C/D=2-531.
DR   PDB; 3G2G; X-ray; 2.00 A; A/B/C/D=1-531.
DR   PDB; 3GQY; X-ray; 1.85 A; A/B/C/D=1-531.
DR   PDB; 3GR4; X-ray; 1.60 A; A/B/C/D=1-531.
DR   PDB; 3H6O; X-ray; 2.00 A; A/B/C/D=1-531.
DR   PDB; 3ME3; X-ray; 1.95 A; A/B/C/D=1-531.
DR   PDB; 3SRD; X-ray; 2.90 A; A/B/C/D=1-531.
DR   PDB; 3SRF; X-ray; 2.84 A; A/B/C/D/E/F/G/H=1-531.
DR   PDB; 3SRH; X-ray; 2.60 A; A/B/C/D=1-531.
DR   PDB; 3U2Z; X-ray; 2.10 A; A/B/C/D=1-531.
DR   PDB; 4B2D; X-ray; 2.30 A; A/B/C/D=2-531.
DR   PDB; 4FXF; X-ray; 2.55 A; A/B/C/D=1-531.
DR   PDB; 4FXJ; X-ray; 2.90 A; A/B/C/D=1-531.
DR   PDB; 4G1N; X-ray; 2.30 A; A/B/C/D=14-531.
DR   PDB; 4JPG; X-ray; 2.33 A; A/B/C/D=1-531.
DR   PDB; 4QG6; X-ray; 3.21 A; A/B/C/D=1-531.
DR   PDB; 4QG8; X-ray; 2.30 A; A/B/C/D=1-531.
DR   PDB; 4QG9; X-ray; 2.38 A; A/B/C/D=1-531.
DR   PDB; 4QGC; X-ray; 2.30 A; A/B/C/D=1-531.
DR   PDB; 4RPP; X-ray; 2.58 A; A/B/C/D=1-531.
DR   PDB; 4WJ8; X-ray; 2.87 A; A/B/C/D=1-531.
DR   PDB; 4YJ5; X-ray; 2.41 A; A/B/C/D=14-531.
DR   PDBsum; 1T5A; -.
DR   PDBsum; 1ZJH; -.
DR   PDBsum; 3BJF; -.
DR   PDBsum; 3BJT; -.
DR   PDBsum; 3G2G; -.
DR   PDBsum; 3GQY; -.
DR   PDBsum; 3GR4; -.
DR   PDBsum; 3H6O; -.
DR   PDBsum; 3ME3; -.
DR   PDBsum; 3SRD; -.
DR   PDBsum; 3SRF; -.
DR   PDBsum; 3SRH; -.
DR   PDBsum; 3U2Z; -.
DR   PDBsum; 4B2D; -.
DR   PDBsum; 4FXF; -.
DR   PDBsum; 4FXJ; -.
DR   PDBsum; 4G1N; -.
DR   PDBsum; 4JPG; -.
DR   PDBsum; 4QG6; -.
DR   PDBsum; 4QG8; -.
DR   PDBsum; 4QG9; -.
DR   PDBsum; 4QGC; -.
DR   PDBsum; 4RPP; -.
DR   PDBsum; 4WJ8; -.
DR   PDBsum; 4YJ5; -.
DR   ProteinModelPortal; P14618; -.
DR   SMR; P14618; -.
DR   BioGrid; 111332; 180.
DR   DIP; DIP-31273N; -.
DR   IntAct; P14618; 242.
DR   MINT; MINT-4998892; -.
DR   STRING; 9606.ENSP00000320171; -.
DR   BindingDB; P14618; -.
DR   ChEMBL; CHEMBL1075189; -.
DR   DrugBank; DB02726; 2-Phosphoglycolic Acid.
DR   DrugBank; DB01733; L-Phospholactate.
DR   DrugBank; DB00119; Pyruvic acid.
DR   iPTMnet; P14618; -.
DR   PhosphoSitePlus; P14618; -.
DR   SwissPalm; P14618; -.
DR   BioMuta; PKM; -.
DR   DMDM; 20178296; -.
DR   DOSAC-COBS-2DPAGE; P14618; -.
DR   OGP; P14618; -.
DR   REPRODUCTION-2DPAGE; IPI00220644; -.
DR   REPRODUCTION-2DPAGE; IPI00479186; -.
DR   UCD-2DPAGE; P14618; -.
DR   EPD; P14618; -.
DR   PaxDb; P14618; -.
DR   PeptideAtlas; P14618; -.
DR   PRIDE; P14618; -.
DR   TopDownProteomics; P14618-1; -. [P14618-1]
DR   TopDownProteomics; P14618-2; -. [P14618-2]
DR   DNASU; 5315; -.
DR   Ensembl; ENST00000319622; ENSP00000320171; ENSG00000067225. [P14618-2]
DR   Ensembl; ENST00000335181; ENSP00000334983; ENSG00000067225. [P14618-1]
DR   Ensembl; ENST00000449901; ENSP00000403365; ENSG00000067225. [P14618-3]
DR   Ensembl; ENST00000565154; ENSP00000455901; ENSG00000067225. [P14618-2]
DR   Ensembl; ENST00000565184; ENSP00000455736; ENSG00000067225. [P14618-2]
DR   Ensembl; ENST00000568459; ENSP00000456970; ENSG00000067225. [P14618-2]
DR   GeneID; 5315; -.
DR   KEGG; hsa:5315; -.
DR   UCSC; uc002atw.2; human. [P14618-1]
DR   CTD; 5315; -.
DR   DisGeNET; 5315; -.
DR   GeneCards; PKM; -.
DR   HGNC; HGNC:9021; PKM.
DR   HPA; CAB019421; -.
DR   HPA; HPA029501; -.
DR   MalaCards; PKM; -.
DR   MIM; 179050; gene.
DR   neXtProt; NX_P14618; -.
DR   OpenTargets; ENSG00000067225; -.
DR   PharmGKB; PA33353; -.
DR   eggNOG; KOG2323; Eukaryota.
DR   eggNOG; COG0469; LUCA.
DR   GeneTree; ENSGT00390000008859; -.
DR   HOGENOM; HOG000021559; -.
DR   HOVERGEN; HBG000941; -.
DR   InParanoid; P14618; -.
DR   KO; K00873; -.
DR   OMA; KQHGGEH; -.
DR   PhylomeDB; P14618; -.
DR   TreeFam; TF300390; -.
DR   BioCyc; MetaCyc:HS00906-MONOMER; -.
DR   BRENDA; 2.7.1.40; 2681.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-70171; Glycolysis.
DR   SABIO-RK; P14618; -.
DR   SIGNOR; P14618; -.
DR   UniPathway; UPA00109; UER00188.
DR   EvolutionaryTrace; P14618; -.
DR   GeneWiki; PKM2; -.
DR   GenomeRNAi; 5315; -.
DR   PRO; PR:P14618; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000067225; -.
DR   CleanEx; HS_PKM2; -.
DR   ExpressionAtlas; P14618; baseline and differential.
DR   Genevisible; P14618; HS.
DR   GO; GO:0005929; C:cilium; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1903561; C:extracellular vesicle; IDA:UniProtKB.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0043209; C:myelin sheath; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0031982; C:vesicle; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0016301; F:kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0023026; F:MHC class II protein complex binding; IDA:UniProtKB.
DR   GO; GO:0030955; F:potassium ion binding; IEA:InterPro.
DR   GO; GO:0004743; F:pyruvate kinase activity; IDA:CACAO.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0061621; P:canonical glycolysis; TAS:Reactome.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IBA:GO_Central.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0012501; P:programmed cell death; IDA:UniProtKB.
DR   CDD; cd00288; Pyruvate_Kinase; 1.
DR   Gene3D; 3.40.1380.20; -; 1.
DR   InterPro; IPR001697; Pyr_Knase.
DR   InterPro; IPR015813; Pyrv/PenolPyrv_Kinase-like_dom.
DR   InterPro; IPR011037; Pyrv_Knase-like_insert_dom.
DR   InterPro; IPR018209; Pyrv_Knase_AS.
DR   InterPro; IPR015793; Pyrv_Knase_brl.
DR   InterPro; IPR015795; Pyrv_Knase_C.
DR   PANTHER; PTHR11817; PTHR11817; 1.
DR   Pfam; PF00224; PK; 1.
DR   Pfam; PF02887; PK_C; 1.
DR   PRINTS; PR01050; PYRUVTKNASE.
DR   SUPFAM; SSF50800; SSF50800; 1.
DR   SUPFAM; SSF51621; SSF51621; 2.
DR   SUPFAM; SSF52935; SSF52935; 1.
DR   TIGRFAMs; TIGR01064; pyruv_kin; 1.
DR   PROSITE; PS00110; PYRUVATE_KINASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Allosteric enzyme; Alternative splicing;
KW   ATP-binding; Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Glycolysis; Hydroxylation; Isopeptide bond; Kinase; Magnesium;
KW   Metal-binding; Methylation; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Potassium; Pyruvate; Reference proteome;
KW   Transferase; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:25944712,
FT                                ECO:0000269|PubMed:12665801,
FT                                ECO:0000269|PubMed:1854723,
FT                                ECO:0000269|Ref.11}.
FT   CHAIN         2    531       Pyruvate kinase PKM.
FT                                /FTId=PRO_0000112088.
FT   NP_BIND      75     78       ATP. {ECO:0000244|PDB:4FXF,
FT                                ECO:0000269|PubMed:23530218}.
FT   REGION      307    531       Interaction with POU5F1.
FT                                {ECO:0000269|PubMed:18191611}.
FT   REGION      389    433       Intersubunit contact.
FT   REGION      432    437       D-fructose 1,6-bisphosphate binding; part
FT                                of allosteric site.
FT                                {ECO:0000244|PDB:1T5A,
FT                                ECO:0000244|PDB:4FXF,
FT                                ECO:0000269|PubMed:15996096,
FT                                ECO:0000269|PubMed:23530218}.
FT   REGION      516    521       D-fructose 1,6-bisphosphate binding; part
FT                                of allosteric site.
FT                                {ECO:0000244|PDB:1T5A,
FT                                ECO:0000244|PDB:4FXF,
FT                                ECO:0000269|PubMed:15996096,
FT                                ECO:0000269|PubMed:23530218}.
FT   METAL        75     75       Potassium. {ECO:0000244|PDB:4FXF,
FT                                ECO:0000269|PubMed:23530218}.
FT   METAL        77     77       Potassium. {ECO:0000244|PDB:4FXF,
FT                                ECO:0000269|PubMed:23530218}.
FT   METAL       113    113       Potassium. {ECO:0000244|PDB:4FXF,
FT                                ECO:0000269|PubMed:23530218}.
FT   METAL       114    114       Potassium; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:4FXF,
FT                                ECO:0000269|PubMed:23530218}.
FT   METAL       272    272       Magnesium. {ECO:0000244|PDB:4FXF,
FT                                ECO:0000269|PubMed:23530218}.
FT   METAL       296    296       Magnesium. {ECO:0000244|PDB:4FXF,
FT                                ECO:0000269|PubMed:23530218}.
FT   BINDING      70     70       Serine.
FT   BINDING      73     73       Substrate.
FT                                {ECO:0000250|UniProtKB:P30613}.
FT   BINDING     106    106       Serine.
FT   BINDING     120    120       ATP. {ECO:0000244|PDB:4FXF,
FT                                ECO:0000269|PubMed:23530218}.
FT   BINDING     207    207       ATP. {ECO:0000244|PDB:4FXF,
FT                                ECO:0000269|PubMed:23530218}.
FT   BINDING     270    270       Substrate; via amide nitrogen.
FT                                {ECO:0000250|UniProtKB:P30613}.
FT   BINDING     295    295       Substrate; via amide nitrogen.
FT                                {ECO:0000250|UniProtKB:P30613}.
FT   BINDING     296    296       Substrate; via amide nitrogen.
FT                                {ECO:0000250|UniProtKB:P30613}.
FT   BINDING     328    328       Substrate.
FT                                {ECO:0000250|UniProtKB:P30613}.
FT   BINDING     464    464       Serine.
FT   BINDING     482    482       D-fructose 1,6-bisphosphate; part of
FT                                allosteric site. {ECO:0000244|PDB:1T5A,
FT                                ECO:0000244|PDB:4FXF,
FT                                ECO:0000269|PubMed:15996096,
FT                                ECO:0000269|PubMed:23530218}.
FT   BINDING     489    489       D-fructose 1,6-bisphosphate; part of
FT                                allosteric site. {ECO:0000244|PDB:1T5A,
FT                                ECO:0000244|PDB:4FXF,
FT                                ECO:0000269|PubMed:15996096,
FT                                ECO:0000269|PubMed:23530218}.
FT   SITE        270    270       Transition state stabilizer.
FT                                {ECO:0000250|UniProtKB:P00549}.
FT   SITE        433    433       Crucial for phosphotyrosine binding.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:25944712,
FT                                ECO:0000269|Ref.11}.
FT   MOD_RES       3      3       N6,N6,N6-trimethyllysine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES      37     37       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18088087,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES      41     41       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      62     62       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      66     66       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P52480}.
FT   MOD_RES      89     89       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      97     97       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P11980}.
FT   MOD_RES     100    100       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P11980}.
FT   MOD_RES     105    105       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     127    127       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     148    148       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P52480}.
FT   MOD_RES     166    166       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     166    166       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P52480}.
FT   MOD_RES     175    175       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     195    195       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     249    249       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P30613}.
FT   MOD_RES     266    266       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     270    270       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P52480}.
FT   MOD_RES     305    305       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:21700219}.
FT   MOD_RES     322    322       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P52480}.
FT   MOD_RES     322    322       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P52480}.
FT   MOD_RES     403    403       4-hydroxyproline.
FT                                {ECO:0000269|PubMed:21620138}.
FT   MOD_RES     408    408       4-hydroxyproline.
FT                                {ECO:0000269|PubMed:21620138}.
FT   MOD_RES     433    433       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     475    475       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P52480}.
FT   MOD_RES     498    498       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P52480}.
FT   CROSSLNK    166    166       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1);
FT                                alternate. {ECO:0000244|PubMed:25114211}.
FT   VAR_SEQ       1     82       MSKPHSEAGTAFIQTQQLHAAMADTFLEHMCRLDIDSPPIT
FT                                ARNTGIICTIGPASRSVETLKEMIKSGMNVARLNFSHGTHE
FT                                -> MSPEAQPQRTKGPQQPCRSPIVKPGLPSFRPSSCTQPW
FT                                LTHSWSTCAAWTLIHHPSQPGTLASSVPL (in isoform
FT                                3). {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043370.
FT   VAR_SEQ     389    433       IYHLQLFEELRRLAPITSDPTEATAVGAVEASFKCCSGAII
FT                                VLTK -> MFHRKLFEELVRASSHSTDLMEAMAMGSVEASY
FT                                KCLAAALIVLTE (in isoform M1).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_011101.
FT   VARIANT     204    204       G -> V (in dbSNP:rs17853396).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_033067.
FT   MUTAGEN     403    403       P->A: Significant reduction in
FT                                hydroxylation and in PKM-mediated
FT                                transcriptional activity of HIF1A; when
FT                                associated with A-408.
FT                                {ECO:0000269|PubMed:21620138}.
FT   MUTAGEN     408    408       P->A: Significant reduction in
FT                                hydroxylation and in PKM-mediated
FT                                transcriptional activity of HIF1A; when
FT                                associated with A-403.
FT                                {ECO:0000269|PubMed:21620138}.
FT   MUTAGEN     437    437       S->Y: Unable to bind FBP but still
FT                                activated by serine.
FT                                {ECO:0000269|PubMed:23064226}.
FT   MUTAGEN     464    464       H->A: Abolishes serine binding and
FT                                allosteric activation.
FT                                {ECO:0000269|PubMed:23064226}.
FT   CONFLICT      7      7       E -> Q (in Ref. 10; AAH12811).
FT                                {ECO:0000305}.
FT   CONFLICT     54     54       A -> T (in Ref. 5; BAG52542).
FT                                {ECO:0000305}.
FT   CONFLICT    103    103       I -> Y (in Ref. 2; AAA36672).
FT                                {ECO:0000305}.
FT   CONFLICT    132    132       V -> L (in Ref. 2; AAA36672).
FT                                {ECO:0000305}.
FT   CONFLICT    187    187       Q -> R (in Ref. 6; BAD96647).
FT                                {ECO:0000305}.
FT   CONFLICT    252    252       H -> R (in Ref. 6; BAD96647).
FT                                {ECO:0000305}.
FT   CONFLICT    339    339       R -> P (in Ref. 4; CAA39849).
FT                                {ECO:0000305}.
FT   CONFLICT    349    349       A -> V (in Ref. 5; BAG52542).
FT                                {ECO:0000305}.
FT   CONFLICT    379    379       H -> N (in Ref. 1; AAA36449).
FT                                {ECO:0000305}.
FT   CONFLICT    507    507       D -> H (in Ref. 10; AAH12811).
FT                                {ECO:0000305}.
FT   HELIX        15     17       {ECO:0000244|PDB:4WJ8}.
FT   HELIX        18     21       {ECO:0000244|PDB:3GR4}.
FT   HELIX        26     31       {ECO:0000244|PDB:3GR4}.
FT   STRAND       35     37       {ECO:0000244|PDB:4QGC}.
FT   STRAND       45     50       {ECO:0000244|PDB:3GR4}.
FT   TURN         53     55       {ECO:0000244|PDB:3GR4}.
FT   HELIX        58     67       {ECO:0000244|PDB:3GR4}.
FT   STRAND       71     75       {ECO:0000244|PDB:3GR4}.
FT   HELIX        76     78       {ECO:0000244|PDB:4QG6}.
FT   HELIX        81     96       {ECO:0000244|PDB:3GR4}.
FT   TURN         97    100       {ECO:0000244|PDB:3GR4}.
FT   TURN        102    104       {ECO:0000244|PDB:3GR4}.
FT   STRAND      109    113       {ECO:0000244|PDB:3GR4}.
FT   STRAND      119    121       {ECO:0000244|PDB:3ME3}.
FT   STRAND      127    129       {ECO:0000244|PDB:3GQY}.
FT   STRAND      132    134       {ECO:0000244|PDB:3GR4}.
FT   STRAND      139    143       {ECO:0000244|PDB:3GR4}.
FT   HELIX       146    148       {ECO:0000244|PDB:3GR4}.
FT   STRAND      154    160       {ECO:0000244|PDB:3GR4}.
FT   HELIX       164    167       {ECO:0000244|PDB:3GR4}.
FT   STRAND      173    176       {ECO:0000244|PDB:3GR4}.
FT   TURN        177    180       {ECO:0000244|PDB:3GR4}.
FT   STRAND      181    188       {ECO:0000244|PDB:3GR4}.
FT   STRAND      190    199       {ECO:0000244|PDB:3GR4}.
FT   STRAND      201    203       {ECO:0000244|PDB:3GR4}.
FT   STRAND      204    206       {ECO:0000244|PDB:4B2D}.
FT   STRAND      208    210       {ECO:0000244|PDB:3GR4}.
FT   STRAND      212    214       {ECO:0000244|PDB:4JPG}.
FT   HELIX       223    234       {ECO:0000244|PDB:3GR4}.
FT   STRAND      238    242       {ECO:0000244|PDB:3GR4}.
FT   HELIX       248    258       {ECO:0000244|PDB:3GR4}.
FT   TURN        259    264       {ECO:0000244|PDB:3GR4}.
FT   STRAND      265    271       {ECO:0000244|PDB:3GR4}.
FT   HELIX       274    278       {ECO:0000244|PDB:3GR4}.
FT   HELIX       280    286       {ECO:0000244|PDB:3GR4}.
FT   STRAND      287    293       {ECO:0000244|PDB:3GR4}.
FT   HELIX       294    300       {ECO:0000244|PDB:3GR4}.
FT   HELIX       303    305       {ECO:0000244|PDB:3GR4}.
FT   HELIX       306    320       {ECO:0000244|PDB:3GR4}.
FT   STRAND      324    329       {ECO:0000244|PDB:3GR4}.
FT   HELIX       332    335       {ECO:0000244|PDB:3GR4}.
FT   STRAND      337    339       {ECO:0000244|PDB:3BJT}.
FT   HELIX       342    354       {ECO:0000244|PDB:3GR4}.
FT   STRAND      357    362       {ECO:0000244|PDB:3GR4}.
FT   HELIX       363    366       {ECO:0000244|PDB:3GR4}.
FT   STRAND      367    369       {ECO:0000244|PDB:1ZJH}.
FT   HELIX       371    387       {ECO:0000244|PDB:3GR4}.
FT   HELIX       391    401       {ECO:0000244|PDB:3GR4}.
FT   TURN        402    404       {ECO:0000244|PDB:3SRF}.
FT   HELIX       408    422       {ECO:0000244|PDB:3GR4}.
FT   STRAND      428    431       {ECO:0000244|PDB:3GR4}.
FT   STRAND      433    435       {ECO:0000244|PDB:3GR4}.
FT   HELIX       436    442       {ECO:0000244|PDB:3GR4}.
FT   STRAND      450    455       {ECO:0000244|PDB:3GR4}.
FT   HELIX       457    462       {ECO:0000244|PDB:3GR4}.
FT   HELIX       463    465       {ECO:0000244|PDB:3GR4}.
FT   STRAND      469    473       {ECO:0000244|PDB:3GR4}.
FT   HELIX       482    499       {ECO:0000244|PDB:3GR4}.
FT   STRAND      508    518       {ECO:0000244|PDB:3GR4}.
FT   STRAND      522    529       {ECO:0000244|PDB:3GR4}.
SQ   SEQUENCE   531 AA;  57937 MW;  AA94D7818ED6BBAD CRC64;
     MSKPHSEAGT AFIQTQQLHA AMADTFLEHM CRLDIDSPPI TARNTGIICT IGPASRSVET
     LKEMIKSGMN VARLNFSHGT HEYHAETIKN VRTATESFAS DPILYRPVAV ALDTKGPEIR
     TGLIKGSGTA EVELKKGATL KITLDNAYME KCDENILWLD YKNICKVVEV GSKIYVDDGL
     ISLQVKQKGA DFLVTEVENG GSLGSKKGVN LPGAAVDLPA VSEKDIQDLK FGVEQDVDMV
     FASFIRKASD VHEVRKVLGE KGKNIKIISK IENHEGVRRF DEILEASDGI MVARGDLGIE
     IPAEKVFLAQ KMMIGRCNRA GKPVICATQM LESMIKKPRP TRAEGSDVAN AVLDGADCIM
     LSGETAKGDY PLEAVRMQHL IAREAEAAIY HLQLFEELRR LAPITSDPTE ATAVGAVEAS
     FKCCSGAIIV LTKSGRSAHQ VARYRPRAPI IAVTRNPQTA RQAHLYRGIF PVLCKDPVQE
     AWAEDVDLRV NFAMNVGKAR GFFKKGDVVI VLTGWRPGSG FTNTMRVVPV P
//
